Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 3266
IPSCIO Record ID: 113052
The company is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company maintains two active business segments BioTherapeutics and Vaccines/BioDefense.
The Companyâ€™s BioTherapeutics business segment is developing a first-in-class photodynamic therapy (SGX301) utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (â€œCTCLâ€), proprietary formulations of oral beclomethasone 17, 21-dipropionate (â€œBDPâ€) for the prevention/treatment of gastrointestinal (â€œGIâ€) disorders characterized by severe inflammation, including pediatric Crohnâ€™s disease (SGX203) and acute radiation enteritis (SGX201), and itâ€™s novel innate defense regulator (â€œIDRâ€) technology dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.
The Companyâ€™s Vaccines/BioDefense business segment includes active development programs for RiVaxâ„¢, its ricin toxin vaccine candidate, VeloThraxâ„¢, an anthrax vaccine candidate, OrbeShieldÂ®, a GI acute radiation syndrome (â€œGI ARSâ€) therapeutic candidate and SGX943, a melioidosis therapeutic candidate. The development of the vaccine programs currently supported by the heat stabilization technology, known as ThermoVaxÂ®, under existing and on-going government contract funding. With the government contract from the National Institute of Allergy and Infectious Diseases (â€œNIAIDâ€), the Company will attempt to advance the development of RiVaxâ„¢ to protect against exposure to ricin toxin. The Company plans to use the funds received under the government contracts with the Biomedical Advanced Research and Development Authority (â€œBARDAâ€) and NIAID to advance the development of OrbeShieldÂ® for the treatment of GI ARS.
IPSCIO Record ID: 798
orBecÂ® is for the treatment of acute GI GVHD, which is expected to occur in the second half of 2009. GVHD occurs in patients following allogeneic bone marrow transplantation in which tissues of the host, most frequently the gut, liver, and skin, are attacked by lymphocytes from the donor (graft) marrow.
IPSCIO Record ID: 7344
RMS RPC1063 is a novel, oral, once daily, selective and potent S1P1R modulator. RMS is a chronic autoimmune disorder of the central nervous system (CNS), characterized by recurrent acute exacerbations (relapses) of neurological dysfunction followed by variable degrees of recovery with clinical stability between relapses (remission).
RPC1063 for the treatment of UC IBD is comprised of two chronic, autoimmune, GI inflammatory disorders UC and Crohn's Disease (CD). UC is a GI inflammatory disorder involving ulcers in the colon and is characterized by a chronic course of remissions and exacerbations. Patients suffer from a multitude of GI symptoms, including diarrhea, rectal bleeding and abdominal pain.